Signaturefd LLC Buys 22,148 Shares of Novo Nordisk A/S $NVO

Key Points

• Signaturefd LLC increased its Novo Nordisk position by 41.3% in the second quarter, purchasing 22,148 additional shares and bringing its holdings to 75,831 shares valued at approximately $3.64 million.
• Novo Nordisk reported quarterly revenue of $11.98 billion and earnings of $0.94 per share, with a 35.36% net margin and 61.20% return on equity. The stock opened at $46.75 and has traded between $35.12 and $64.16 over the past year.
• Analysts remain cautious, with a consensus “Hold” rating and a $64.94 price target. While oral Wegovy offers growth potential, intensifying competition from Eli Lilly, pricing pressure and concerns about Wegovy sales pose risks.

Signaturefd LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 41.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 75,831 shares of the company's stock after purchasing an additional 22,148 shares during the quarter. Signaturefd LLC's holdings in Novo Nordisk A/S were worth $3,635,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Capital Investment Counsel LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $3,727,000. Marathon Capital Management lifted its stake in shares of Novo Nordisk A/S by 43.9% in the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company's stock valued at $4,208,000 after purchasing an additional 25,230 shares during the period. Burkett Asset Management Ltd purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $1,823,000. Tevis Investment Management grew its position in Novo Nordisk A/S by 65.7% during the first quarter. Tevis Investment Management now owns 74,090 shares of the company's stock valued at $2,813,000 after buying an additional 29,390 shares during the period. Finally, Myriad Asset Management Advisors LLC purchased a new position in Novo Nordisk A/S in the second quarter valued at $1,846,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $46.75 on Friday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $208.74 billion, a P/E ratio of 11.43, a price-to-earnings-growth ratio of 4.23 and a beta of 0.76. The firm has a 50-day moving average price of $47.30 and a two-hundred day moving average price of $44.50. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. As a group, research analysts expect that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be issued a dividend of $0.5786 per share. This represents a dividend yield of 254.0%. The ex-dividend date of this dividend is Monday, August 17th. Novo Nordisk A/S's payout ratio is 42.79%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVO. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday. BMO Capital Markets reaffirmed a "market perform" rating and set a $47.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Berenberg Bank set a $47.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday. HSBC reissued a "hold" rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Finally, Weiss Ratings upgraded Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $64.94.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market will not be “winner-take-all,” arguing that patients’ differing preferences and demand for pills, injectables and other differentiated treatments should support multiple successful players. Reuters article
• Positive Sentiment: Novo’s oral Wegovy appears to be generating strong prescription momentum, offering a potential new growth channel and helping the company compete beyond its injectable portfolio. However, investors are watching whether that momentum can offset Lilly’s faster growth. Zacks article
• Positive Sentiment: Zacks Research upgraded NVO from “strong sell” to “hold,” indicating that the stock’s sharp decline and low earnings multiple may have reduced some downside risk.
• Neutral Sentiment: Novo defended its lawsuit challenging Eli Lilly’s weight-loss advertising, saying competition must be fair. The litigation could protect Novo’s marketing position, but it also highlights the intensity of the competitive battle. CNBC article
• Neutral Sentiment: Novo’s CEO continues to promote a long runway for obesity treatments, citing low overall adoption and potential healthcare-cost benefits. These are long-term opportunities rather than immediate earnings catalysts. Fox Business article
• Negative Sentiment: Eli Lilly’s growing share in both injectable and oral weight-loss drugs is the main concern. Analysts warn that Lilly’s momentum could widen the competitive gap and limit the upside investors had anticipated from the Wegovy pill. Yahoo Finance article
• Negative Sentiment: Berenberg downgraded Novo from “buy” to “hold,” citing expectations that the initial Wegovy-pill upside is already reflected in the stock and valuing the company closer to the broader European pharmaceutical sector.
• Negative Sentiment: Recent analysis also points to flat Wegovy sales, pricing pressure and pipeline setbacks as near-term risks, helping explain why NVO has decreased despite its strong margins and broader cardiometabolic pipeline. Zacks analysis

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source